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Abstract
With the frequency of cases of Clostridium difﬁcile infection (CDI) increasing in many developed countries, accurate and reliable labora-
tory diagnosis of CDI is more important than ever. However, the diagnosis of CDI has been handicapped by the existence of two refer-
ence standards, one of which detects C. difﬁcile toxin (cytotoxin assay) and the other only toxigenic strains (cytotoxigenic culture).
Being relatively slow and laborious to perform, these reference methods were largely abandoned as routine diagnostic methods for
toxin detection in favour of stand-alone rapid enzyme immunoassays (EIAs), which have suboptimal sensitivity and speciﬁcity. The man-
agement of CDI is undermined by high rates of both false-positive and false-negative test results. More recently developed nucleic acid
ampliﬁcation tests (NAATs) for toxin gene detection offer improved sensitivity over immunoassays, but fail to discriminate between
CDI and asymptomatic colonization with C. difﬁcile, and have clear drawbacks as stand-alone diagnostic tests. Two-step or three-step
diagnostic algorithms have been proposed as a solution. In a large study of the effectiveness of currently available tests, a diagnostic
algorithm was developed that combines available tests to more effectively distinguish patients with CDI from uninfected patients. This
two-test protocol, which is now used in National Health Service laboratories in England, comprises an EIA for glutamate dehydrogenase
detection or NAATs for toxin gene detection, followed by a relatively sensitive toxin EIA. This algorithm also identiﬁes ‘potential C. difﬁ-
cile excretors’, individuals with diarrhoeal samples that contain C. difﬁcile but without demonstrable toxin, who may be a source of
transmission of C. difﬁcile to susceptible patients.
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Introduction
Clostridium difﬁcile is recognized as the leading cause of infec-
tious nosocomial diarrhoea in developed countries [1], and is
the main cause of antibiotic-associated pseudomembranous
colitis [2]. The emergence of a hypervirulent strain of C. difﬁ-
cile (ribotype 027), which ﬁrst appeared about a decade ago
in North America and then spread to parts of Europe, has
raised the proﬁle of C. difﬁcile in many countries [3]. None-
theless, in many parts of Europe, C. difﬁcile infection (CDI)
remains an under-recognized disease and is therefore under-
diagnosed and under-reported. A lack of disease awareness
leads to a reduced level of clinical suspicion of CDI and,
potentially, a cycle of reduced requests for CDI testing, less
diagnosis of cases, and potentially increased transmission of
infection.
A lack of consistent diagnostic and screening practices for
CDI across European countries (and even from hospital to
hospital within countries) makes it difﬁcult to estimate the
true number of cases of CDI that occur across Europe each
year. The lack of consistent and accurate diagnostic data
hampers our understanding of the epidemiology of CDI in
Europe, with current incidence and prevalence rates more
likely to reﬂect the testing practices in a particular country
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than the true frequency of CDI cases [4]. Countries where
frequent testing does not occur tend to have a low estimated
rate of diagnosis, whereas countries with frequent testing for
CDI tend to have higher rates of diagnosis—in other words,
the more you test, the more you ﬁnd. This point is particu-
larly well illustrated by data from a recent pan-European epi-
demiological survey of rates of CDI in Europe carried out in
2008 [4]. The survey, which covered between one and six
hospitals in each of the 34 countries surveyed, showed that
testing frequency varied between countries by more than 40
times, ranging from as few as three tests per 10 000 patient-
days to as many as 141 tests per 10 000 patient-days. The
measured incidence of CDI was highest where the frequency
of testing was highest (Fig. 1).
Throughout Europe, there is a need to raise awareness of
C. difﬁcile as a cause of nosocomial diarrhoea, and to stan-
dardize when and how CDI testing occurs. This will help to
ensure that suspected cases of CDI can be diagnosed with
greater accuracy and reliability than at present. It is difﬁcult
to manage patients well and to implement effective infection
control measures without accurate diagnosis of CDI, and, in
turn, interrupting the transmission of infection may be com-
promised. Inaccurate diagnostic protocols also lead to poor
epidemiological data and undermine effective disease surveil-
lance. Accurate diagnosis of CDI is a prerequisite for deter-
mining whether patients need speciﬁc antibiotic therapy for
this infection and, potentially, whether there is also a need
for antibiotic susceptibility testing. With the possible excep-
tion of rifaximin, which is used to treat CDI in some Euro-
pean countries and for which resistance has been identiﬁed
in up to one-quarter of C. difﬁcile isolates [5], there does not
yet seem to be a requirement for susceptibility testing as
part of routine diagnosis.
Based on a presentation that took place during the 22nd
European Congress of Clinical Microbiology and Infectious
Diseases (ECCMID), held in London, UK, from 31 March to
3 April 2012, this review will look at the current state of
diagnostic testing for CDI from a European perspective, and
speciﬁcally at new approaches being adopted in England to
improve the outcome of diagnostic testing for CDI. This
review is not intended to be a comprehensive or systematic
review of the published literature on CDI testing. In addition,
issues relating to the costs and logistics of using two-step
diagnostic testing algorithms in preference to single-test pro-
cedures, although important, are beyond the scope of the
review.
Laboratory Diagnosis of CDI—Still in a
State of Flux
Most patients with CDI present with profuse watery diar-
rhoea that has a distinctive, foul-smelling odour. However,
on its own, this is insufﬁciently reliable for a deﬁnitive diag-
nosis of CDI, because of the many infective and non-infective
causes of diarrhoea. Additional laboratory tests are therefore
needed to conﬁrm a presumptive clinical diagnosis of CDI
[1] (Table 1).
The cell cytotoxicity assay and cytotoxigenic culture have
traditionally been considered to be the reference methods
for the diagnosis of CDI. The ﬁrst detects the presence of
C. difﬁcile toxins, toxin B and toxin A, in a patient’s faecal
sample [1]. By contrast, cytotoxigenic culture detects C. difﬁ-
cile strains that have the capacity to produce toxins. How-
ever, the availability of two reference standards is
problematic, because each method detects a different target,
and the two methods are not directly comparable (Table 1).
Experience from the UK suggests that many laboratories
abandoned the standard reference methods in favour of
more rapid toxin detection kits based on enzyme immunoas-
FIG. 1. Correlation between the frequency of Clostridium difﬁcile
infection (CDI) testing and measured CDI incidence [4].
TABLE 1. Current diagnostic tests for Clostridium difﬁcile in-
fection






C. difﬁcile Anaerobic culture
Glutamate dehydrogenase
(common antigen) enzyme immunoassays
Toxigenic C. difﬁcile Cytotoxigenic culturea
Nucleic acid ampliﬁcation tests, PCR
TcdA, C. difﬁcile toxin A; TcdB, C. difﬁcile toxin B.
aReference test methods detect different targets, and are not directly compara-
ble.
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says (EIAs). A survey carried out in the UK in 1997 showed
that, at that time, only 45% of laboratories used the refer-
ence standards, as compared with 52% that used toxin
detection kits and 31% that used traditional anaerobic cul-
ture [6]. For the past 10–15 years, the laboratory diagnosis
of CDI has relied mainly on the use of EIAs to detect the
presence of the major C. difﬁcile toxins [7]. This is despite
evidence from Brazier (1998), who reviewed data from sev-
eral publications and found that toxin detection kits are
approximately 10–20% less sensitive than the cell cytotoxic-
ity test [8]. With the advent of more sensitive methods, it is
now clear that detection rates with EIA toxin tests may be
even lower than previously published, with as many as 50%
of cases being missed by some assays [9,10]. Diagnostic accu-
racy is undermined by both false-positive and false-negative
test results. False-positive test results for CDI can lead to
unnecessary antibiotic treatment and isolation of patients,
and false-negative test results can lead to a delay in treat-
ment, with the risk of adverse clinical sequelae, such as ful-
minant colitis, and of disease transmission to other patients.
A recent systematic review of six commercial C. difﬁcile
toxin detection assays found that the overall positive predic-
tive value (PPV) was unacceptably low, being <50% in some
cases [11]. Such low PPVs increase the risk of false-positive
results, especially when the prevalence of CDI is low. These
ﬁndings are supported by data from a large study in which
nine commercial toxin detection assays were compared with
standard reference methods. On the basis of a hospital set-
ting with an assumed CDI prevalence rate of 10%, the toxin
detection tests had low–moderate PPVs ranging from 48.6%
to 86.8% [12]. In this study, false-positive and false-negative
results were generally not obtained in the same samples that
were tested by different assays, suggesting that incorrect
diagnoses were attributable to inaccuracies in the toxin
detection kits rather than to other factors. Overall, these
analyses demonstrate that no single immunoassay for the
detection of C. difﬁcile toxin is adequately sensitive or speciﬁc
for the accurate diagnosis of CDI.
Given that EIA toxin detection tests may, at best, fail to
detect CDI in 20% of true cases of CDI, while also falsely
identifying CDI in one or two samples of every ten positives
[7,13], the European Society of Clinical Microbiology and
Infectious Diseases (ESCMID) advocated a two-step
approach to diagnosis [1]. The ESCMID two-step diagnostic
algorithm is based on an initial screening test with a high
negative predictive value (NPV) to identify those individuals
for whom a conﬁrmatory test must be performed in order
to identify a truly positive case of CDI [1] (Fig. 2). The great-
est strength of a two-step diagnostic algorithm as advocated
by the ESCMID is that screening tests, such as assays for
glutamate dehydrogenase (GDH) or nucleic acid ampliﬁcation
tests (NAATs) for C. difﬁcile toxin genes, have high NPVs at
low CDI prevalence, and can thus be used to reliably exclude
patients without infection [1]. This means that negative
results can be issued promptly, and patients with non-CDI
diarrhoea managed appropriately [11]. Some authors have
recently questioned the reliability of assays for GDH and
their use in two-step diagnostic algorithms [14]. Although
the choice of assay method may inﬂuence both sensitivity
and speciﬁcity, as illustrated in the ESCMID analysis, the
reported sensitivity and speciﬁcity of GDH assays generally
exceed 90% [1]. It has also been suggested that the sensitiv-
ity of the GDH assay may be inﬂuenced by the clonal mix of
C. difﬁcile strains in circulation in the hospital environment
[15], although published data on this are limited. When a
positive test result is obtained on initial testing, it can only
FIG. 2. Two-step diagnostic algorithm for Clostridium difﬁcile infection
(CDI) as recommended by the European Society of Clinical Microbi-
ology and Infectious Diseases [1]. EIA, enzyme immunoassay; GDH,
glutamate dehydrogenase; TcdA, C. difﬁcile toxin A; TcdB, C. difﬁcile
toxin B. *A positive toxinogenic culture always indicates the pres-
ence of toxin-producing C. difﬁcile and makes further testing unnec-
essary. Reproduced with permission from Crobach MJT et al.
European Society of Clinical Microbiology and Infectious Diseases
(ESCMID): data review and recommendations for diagnosing Clostrid-
ium difﬁcile-infection (CDI). Clin Microbiol Infect 2009; 15: 1053–1066.
ª 2009 The Authors. ª 2009 European Society of Clinical Microbi-
ology and Infectious Diseases.
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be reported as provisionally positive, and further testing
must be performed with, for example, a toxin detection test
[1,11]. Another potential beneﬁt of a two-step approach to
CDI diagnosis is that it discourages the submission of multi-
ple faecal samples for repeat testing, which studies have
shown can lead to a signiﬁcant increase in the number of
false-positive test results, as well as being highly wasteful of
resources [16,17].
Despite widespread acceptance that a two-step approach
can help to address many of the deﬁciencies that exist with
currently available diagnostic tests for CDI, it has been
inconsistently applied. A comprehensive survey of 170 hospi-
tal trusts in England in 2010, 99% of which responded,
revealed that 70% of their microbiology laboratories used an
EIA toxin detection test as a stand-alone method for CDI,
even though PPVs were as low as 20% in some cases [18].
Failure to provide an accurate and reliable diagnostic service
for CDI undermines mandatory reporting of CDI [19], which
is a requirement in the UK, as well as affecting patient ser-
vices. For example, the survey showed that, in over one-
third of laboratories using stand-alone EIAs for C. difﬁcile
toxins, the probability that a reported positive test result
represented a true case of CDI was <50% [7].
Given that infection control requires CDI patients to be
placed in isolation, cohorting of cases is sometimes used if
there is insufﬁcient single-room capacity. However, if patients
are managed according to diagnostic results of below optimal
accuracy, such a practice risks mixing CDI patients with
patients whose diarrhoea has other causes. False-positive
results can lead to unnecessary antibiotic treatment, with an
increased risk of adverse events, the potential acquisition of
vancomycin-resistant enterococci, and, because of the loss of
colonization resistance, an increased risk of CDI.
Can Molecular Diagnostic Methods Help?
In the search for more accurate diagnostic tests for CDI,
molecular tests that detect the genes encoding C. difﬁcile
toxin A and toxin B have been developed and are now com-
mercially available. NAATs are more sensitive than EIA
detection kits. In the comparative study of nine toxin detec-
tion assays, a PCR for the toxin B gene was more sensitive
than the cell cytotoxicity assay (92.2%) and cytotoxigenic cul-
ture (88.5%). Speciﬁcity in relation to the standard reference
tests was 94.0% and 95.4%, respectively [12]. However,
although detection of toxin genes with NAATs is highly
sensitive and allows differentiation between faecal samples
with and without C. difﬁcile that has toxigenic potential [20],
this does not discriminate between CDI and asymptomatic
colonization with C. difﬁcile. This is probably the greatest
weakness of NAATs, because these assays do not detect the
presence of faecal toxin, without which a diagnosis of CDI
cannot be made with conﬁdence [21].
The distinction between active infection and asymptomatic
colonization with toxigenic C. difﬁcile is important, because
there can be high rates of asymptomatic carriage, especially
among elderly inpatients and those residing in long-term care
or nursing homes, where colonization rates of 10–50% have
been reported [22,23]. Although only diarrhoeal specimens
should be submitted for diagnostic testing for CDI, diarrhoea
is a common symptom among elderly inpatients, many of
whom have received antibiotics or laxatives, or have been
exposed to other pathogens, such as norovirus. Consider-
able potential exists to detect toxigenic C. difﬁcile as an inno-
cent, and possibly protective, bystander. As studies have
demonstrated, colonization by C. difﬁcile may be protective
against the development of CDI when accompanied by a
robust anti-toxin IgG antibody response [22]. Current treat-
ment guidelines also advise against antibiotic treatment of
asymptomatic carriers [24].
The difﬁculty in distinguishing between asymptomatic car-
riage of toxigenic C. difﬁcile and CDI in a patient presenting
with unexplained diarrhoea is illustrated by data from a sur-
vey of elderly hospitalized patients with viral gastroenteritis,
the incidence of which has increased dramatically in recent
years, owing to the emergence of new norovirus variants
[25]. On wards affected by viral gastroenteritis, there was a
signiﬁcant increase in the detection of cytotoxin-positive
cases of CDI. In such cases where the patient presents with
diarrhoea (with or without vomiting), the signiﬁcance of a
C. difﬁcile-positive result, especially where C. difﬁcile toxin is
not sought, is difﬁcult to interpret. For example, do such
patients have CDI and require speciﬁc anti-CDI antibiotic
therapy, or are they just carriers of the bacterium who can
be managed solely with supportive therapy, as for viral gas-
troenteritis?
We know that up to 25% of CDI patients experience
recurrence within 30 days following antibiotic treatment with
either oral metronidazole or vancomycin [26–28]. However,
long-term colonization with C. difﬁcile is also common post-
treatment. In a study of 52 patients with CDI, 56% were
asymptomatic carriers 1–4 weeks after treatment cessation
[29]. These ﬁndings illustrate the difﬁculties in interpreting a
positive C. difﬁcile NAAT result after a primary episode of
CDI if such tests are used as the sole method of laboratory
diagnosis.
The availability of molecular diagnostic tests for CDI rep-
resents an important addition to the existing array of tests,
but they are not a solution for all of the weaknesses of
16 Clinical Microbiology and Infection, Volume 18, Supplement 6, December 2012 CMI
ª2012 The Author
Clinical Microbiology and Infection ª2012 European Society of Clinical Microbiology and Infectious Diseases, CMI, 18 (Suppl. 6), 13–20
earlier testing methods. The new tests deliver relatively rapid
results and high NPVs, but speciﬁcity for CDI is still an issue,
as they detect strains (with toxin genes) rather than the
presence of free toxins. In the author’s opinion, this pre-
cludes their use as stand-alone tests for CDI. Nonetheless, it
is important to acknowledge that this view is not universally
held, and that some laboratories consider NAAT-only testing
to be suitable for the diagnosis of CDI [30], and would rec-
ommend speciﬁc CDI treatment for patients who are PCR-
positive but EIA toxin-negative. Such an approach is open to
debate, but certainly merits independent veriﬁcation in a
prospective study. Given that NAATs detect the toxin gene
and not the toxin, the diagnostic accuracy of molecular-based
testing can probably be enhanced by careful selection of
patients to include only those with true diarrhoea and a
strong clinical suspicion of CDI and, importantly, exclude
patients who have been treated following a laboratory-con-
ﬁrmed diagnosis [31].
Optimizing the Diagnosis of CDI
Currently available rapid tests for the diagnosis of CDI
include EIAs/membrane tests for toxins A and B, immunoas-
says for the common antigen, GDH, and, most recently, NA-
ATs that detect the genes encoding C. difﬁcile toxins A and
B. However, in the author’s opinion, none is yet accurate
enough to be used as a stand-alone diagnostic test for CDI,
a view endorsed in a recent review [31]. With a single diag-
nostic test, improving sensitivity usually compromises speci-
ﬁcity. Theoretically, with combined tests it is possible to get
the best of both worlds, with improved sensitivity (screening
test) and improved speciﬁcity. This rationale underpins the
two-step approach to the diagnosis of CDI, as demonstrated
in the current ESCMID two-step diagnostic algorithm [1].
Understanding the source of C. difﬁcile is also important
for diagnostic purposes, as many clinicians still believe that a
majority of CDI cases occur endogenously, with patients
already harbouring C. difﬁcile on admission to hospital, and
CDI developing following subsequent antibiotic therapy. This
is a common misconception, as asymptomatic carriers of
toxigenic C. difﬁcile are signiﬁcantly less likely than non-carri-
ers to develop CDI [22]. However, asymptomatic carriers
may be a potential reservoir of onward transmission. A
recently published study that used molecular typing to match
cases of nosocomially acquired CDI in >14 000 patients
(1200 cases of CDI) with diarrhoea has highlighted how rela-
tively few cases of CDI could be linked to a ward-based con-
tact. The study revealed that, overall, no more than 25% of
cases could be linked to a potential ward-based inpatient
source; these ‘linkage’ rates varied from 37% in renal/trans-
plant units, to 29% in haematology/oncology units and 28% in
acute/elderly medicine units, with only 6% arising in specialist
surgery units [32]. For these linked cases, the time for puta-
tive onward transmission of CDI for most patients was
between 1 and 4 weeks, with the incubation period from
ward-based contact with donor to recipient typically being
up to 4 weeks. As <25% of CDI cases could be plausibly
linked to other inpatients with CDI, other sources of trans-
mission of C. difﬁcile in the hospital should be explored.
Several studies have alluded to the importance of
asymptomatic C. difﬁcile carriers as a potential source of
transmission [23,29,33]. In a study of elderly patients in a
long-term care facility affected by an outbreak of CDI,
asymptomatic carriers outnumbered symptomatic patients by
seven to one. However, levels of C. difﬁcile contamination on
the skin and in the surrounding environment of carriers
approached those for symptomatic patients, suggesting that
the former may be an important source of onward transmis-
sion [29]. In this respect, it is noteworthy that many CDI
patients in whom diarrhoea resolves following a course of
speciﬁc antibiotic therapy become asymptomatic carriers,
and may continue shedding C. difﬁcile spores for several
weeks after treatment has ended [29]. In optimizing diagnos-
tic algorithms for CDI, we need to be aware of patients who
may not have a laboratory diagnosis of CDI (the primary
purpose of testing), but are nonetheless important as poten-
tial sources of bacterial transmission.
To address current deﬁciencies in diagnostic testing for
CDI and improve mandatory reporting of laboratory detec-
tion of C. difﬁcile, the Department of Health and the Health
Protection Agency in England commissioned a large-scale,
observational study involving four National Health Service
(NHS) laboratories and diarrhoeal faecal samples from
>12 500 patients. With such a large sample size, the accuracy
of the diagnostic testing algorithms could be determined with
high precision [34] (Health Protection Agency website:
http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/131713
2979562). The tests incorporated into the diagnostic algo-
rithms were those routinely used by NHS laboratories, and
included EIAs for C. difﬁcile toxins, toxin gene detection by
PCR, and EIA for GDH, with the cell cytotoxicity assay and
cytotoxigenic culture being used as reference tests (Davies
et al. 22nd ECCMID, 2012, Abstract LB-2817; http://registra
tion.akm.ch/einsicht.php?XNABSTRACT_ID=151898&XNSPR
ACHE_ID=2&XNKONGRESS_ID=161&XNMASKEN_ID=900).
An important objective of the study was to determine the
relative clinical values of the two reference tests for CDI
with respect to patient outcomes, such as 30-day mortality
and morbidity-associated laboratory measurements. The
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results showed that the presence of C. difﬁcile toxin in faecal
samples was signiﬁcantly associated with poor clinical out-
come. Conversely, culture of toxigenic C. difﬁcile in faeces in
the absence of a positive toxin assay result (cytotoxigenic
culture-positive but cytotoxin-negative) was not associated
with any signiﬁcantly worse clinical outcome than that of
negative samples. However, samples containing C. difﬁcile but
with no demonstrable toxin can indicate ‘potential C. difﬁcile
excretors’, and knowledge of this may aid infection preven-
tion and control measures for CDI [34].
These ﬁndings illustrate the importance of redesigning
diagnostic algorithms to facilitate improved understanding of
C. difﬁcile cases among hospitalized patients. To this end, the
results of the 12-month study showed that a diagnostic algo-
rithm based on a test for GDH in combination with a NAAT
for toxigenic C. difﬁcile was optimal for sensitivity [34]
(Davies et al. 22nd ECCMID, 2012, Abstract LB-2817; http://
registration.akm.ch/einsicht.php?XNABSTRACT_ID=151898&
XNSPRACHE_ID=2&XNKONGRESS_ID=161&XNMASKEN_
ID=900). However, the speciﬁcity and corresponding PPV
were poor for this test combination, such that, in approxi-
mately four of 10 of positive results, the patients did not
have a conﬁrmed diagnosis of CDI. Thus, an algorithm based
on these tests would be useful for excluding CDI but poor
at determining whether CDI was truly present. Conversely,
a diagnostic algorithm that combined a toxin EIA with a
NAAT for toxigenic C. difﬁcile yielded the highest speciﬁcity.
The PPV was correspondingly higher (89.0–90.8%) than for
the GDH-based algorithm (59.6–80.7%) according to the
two reference tests. However, high speciﬁcity was achieved
at the expense of sensitivity, so too many cases of CDI
would be missed with this approach.
The most advantageous solution was an algorithm based
on either an EIA for GDH or a NAAT for toxigenic C.
difﬁcile for initial screening, with a follow-up toxin EIA as a
conﬁrmatory test [34] (Davies et al. 22nd ECCMID, 2012,
Abstract LB-2817; http://registration.akm.ch/einsicht.php?
XNABSTRACT_ID=151898&XNSPRACHE_ID=2&XNKON-
GRESS_ID=161&XNMASKEN_ID=900). The caveat here is
that toxin EIAs have variable sensitivity, and so an assay with
(relatively) high sensitivity needs to be used in this algorithm.
In their diagnostic guidance, the ESCMID publish sensitivity
and speciﬁcity rates for a number of EIA toxin detection kits,
in which the sensitivity exceeded 90% for at least two kits
[1]. In our study, the overall performance of the GDH/EIA
toxin algorithm yielded a highly respectable NPV of 98.9%,
demonstrating the algorithm’s ability to correctly rule out
CDI cases, and a PPV of 91.4%, ensuring conﬁdence in the
detection of most cases of CDI. As a result, this diagnostic
algorithm for CDI was recommended for introduction to all
NHS laboratories in England from April 2012, with results
(consistent with CDI) being used for mandatory reporting
(Fig. 3). Also, with this new NHS diagnostic algorithm, it was
possible to identify not only when CDI was or was not likely
to be present, but when C. difﬁcile was probably present (in
an individual with diarrhoea) and the patient was therefore a
‘potential C. difﬁcile excretor’. A PCR test for toxin genes
could be used as an optional third test to determine with
more certainty which GDH-positive, toxin-negative patients
are potential C. difﬁcile excretors [34] (Davies et al. 22nd
ECCMID, 2012, Abstract LB-2817; http://registration.akm.ch/
einsicht.php?XNABSTRACT_ID=151898&XNSPRACHE_ID=
2&XNKONGRESS_ID=161&XNMASKEN_ID=900). Also, con-
sistent with reports from earlier studies, this research again
showed that C. difﬁcile toxin EIAs are not suitable as stand-
alone tests for the diagnosis of CDI or the detection of C.
difﬁcile [34].
In conclusion, laboratory diagnosis is a crucial part of the
management of patients with suspected CDI, but has been
FIG. 3. Two-step diagnostic algorithm for Clostridium difﬁcile infection
(CDI) in a patient with unexplained diarrhoea (Bristol Stool Chart
types 5–7) [34]. EIA, enzyme immunoassay; GDH, glutamate dehy-
drogenase; NAAT, nucleic acid ampliﬁcation test. SIGHT: S = sus-
pect that a case may be infective when there is no clear alternative
cause for diarrhoea; I = isolate the patient within 2 h; G = gloves
and aprons must be used for all contacts with the patient and their
environment; H = hand-washing with soap and water should be car-
ried out before and after each contact with the patient and the
patient’s environment; T = test the stool for C. difﬁcile by sending
specimen immediately. *Performance of a toxin EIA is not necessary
in cases with a negative GDH EIA (or NAAT) result. Notes: A cell
cytotoxin assay may be considered as an alternative to a sensitive
toxin EIA, but yields slower results (1–2 days), and this will need to
be taken into account in making decisions about infection control.
Reproduced with permission. ª Crown copyright 2012; http://
www.nationalarchives.gov.uk/doc/open-government-licence/open-
government-licence.htm
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handicapped by a plethora of testing methods, the lack of a
single reference method, and a growing reliance on stand-
alone rapid diagnostic procedures, such as EIAs, for toxin
detection. The result has been confusion and suboptimal
testing. A growing body of evidence supports the use of a
combination of tests for optimal laboratory diagnosis of CDI.
An algorithm developed in UK laboratories and based on a
two-step approach of GDH EIA (or PCR) to screen samples
followed by a (relatively) sensitive conﬁrmatory toxin EIA
test is now recommended in NHS laboratories in England as
the basis for testing and mandatory reporting of CDI. This
algorithm has the additional advantage of being able to iden-
tify (symptomatic) potential C. difﬁcile excretors. Although no
speciﬁc treatment is indicated for such individuals, their iden-
tiﬁcation offers a possible way of reducing CDI risk for other
patients. Finally, as this review has highlighted, the more you
test for C. difﬁcile, the more you will ﬁnd.
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